TNF and rheumatoid arthritis: Biological disease-modifying antirheumatic drugs (bDMARDs), such as tumor necrosis factor (TNF) inhibitors, are recommended for the treatment of rheumatoid arthritis (RA) when disease activity remains moderate or high despite conventional synthetic DMARD (csDMARD) monotherapy [1].